[Effect of heterologous antilymphocyte globulin in chronic lymphoid leukemia].
D000818:Animals; D000961:Antilymphocyte Serum / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001168:Arthritis / Q000139:chemically induced; D001772:Blood Cell Count; D005334:Fever / Q000139:chemically induced; D006261:Headache / Q000139:chemically induced; D006736:Horses; D006801:Humans; D007415:Intestinal Obstruction / Q000139:chemically induced; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D013921:Thrombocytopenia / Q000139:chemically induced; D014581:Urticaria / Q000139:chemically induced; D014652:Vascular Diseases / Q000139:chemically induced; D014680:Veins
D000961:Antilymphocyte Serum
Uber die Wirkung von heterologem Antilymphozytenglobulin bei chronischer lymphatischer Leukämie.